Jump to Main Contents
研究所ロゴ

Home > Organization > Divisions and Independent Research Units > Group for Development of Molecular diagnostics and Individualized Therapy > Division of Brain Tumor Translational Research > Research Papers

Research Papers

Publications (2012-2017)

  1. Nomura M, Mukasa A, Nagae G, Yamamoto S, Tatsuno K, Ueda H, Fukuda S, Umeda T, Suzuki T, Otani R, Kobayashi K, Maruyama T, Tanaka S, Takayanagi S, Nejo T, Takahashi S, Ichimura K, Nakamura T, Muragaki Y, Narita Y, Nagane M, Ueki K, Nishikawa R, Shibahara J, Aburatani H, Saito N. “Distinct molecular profile of diffuse cerebellar gliomas.” Acta Neuropathol 2017 doi: 10.1007/s00401-017-1771-1. [Epub ahead of print]

  2. Nakamura T, Fukuoka K, Ikeda J, Yoshitomi M, Udaka N, Tanoshima R, Tateishi K, Yamanaka S, Ichimura K, Yamamoto T. “Encouraging option of multi-staged gross total resection for a C11orf-RelA fusion-positive supratentorial anaplastic ependymoma.” Brain Tumor Pathol. 2017 doi: 10.1007/s10014-017-0297-5. [Epub ahead of print]

  3. Takayanagi S, Mukasa A, Tanaka S, Nomura M, Omata M, Yanagisawa S, Yamamoto S, Ichimura K, Nakatomi H, Ueki K, Aburatani H, Saito N. “Differences in genetic and epigenetic alterations between von Hippel-Lindau disease-related and sporadic hemangioblastomas of the central nervous system.” Neuro Oncol 2017 [Epub ahead of print]

  4. Fukushima S, Yamashita S, Kobayashi H, Takami H, Fukuoka K, Nakamura T, Yamasaki K, Matsushita Y, Nakamura H, Totoki Y, Kato M, Suzuki T, Mishima K, Yanagisawa T, Mukasa A, Saito N, Kanamori M, Kumabe T, Tominaga T, Nagane M, Iuchi T, Yoshimoto K, Mizoguchi M, Tamura K, Sakai K, Sugiyama K, Nakada M, Yokogami K, Takeshima H, Kanemura Y, Matsuda M, Matsumura A, Kurozumi K, Ueki K, Nonaka M, Asai A, Kawahara N, Hirose Y, Takayama T, Nakazato Y, Narita Y, Shibata T, Matsutani M, Ushijima T, Nishikawa R, Ichimura K; Intracranial Germ Cell Tumor Genome Analysis Consortium (The iGCTConsortium). “Genome-wide methylation profiles in primary intracranial germ cell tumors indicate a primordial germ cell origin for germinomas.” Acta Neuropathol 133(3):445-462, 2017

  5. Nakamura T, Yamashita S, Fukumura K, Nakabayashi J, Tanaka K, Tamura K, Tateishi K, Kinoshita M, Fukushima S, Takami H, Fukuoka K, Yamazaki K, Matsushita Y, Ohno M, Miyakita Y, Shibui S, Kubo A, Shuto T, Kocialkowski S, Yamanaka S, Mukasa A, Sasayama T, Mishima K, Maehara T, Kawahara N, Nagane M, Narita Y, Mano H, Ushijima T, Ichimura K. “Genome-wide DNA methylation profiling identifies primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma.” Acta Neuropathol 133(2):321-324, 2017

  6. Pajtler KW, Mack SC, Ramaswamy V, Smith CA, Witt H, Smith A, Hansford JR, von Hoff K, Wright KD, Hwang E, Frappaz D, Kanemura Y, Massimino M, Faure-Conter C, Modena P, Tabori U, Warren KE, Holland EC, Ichimura K, Giangaspero F, Castel D, von Deimling A, Kool M, Dirks PB, Grundy RG, Foreman NK, Gajjar A, Korshunov A, Finlay J, Gilbertson RJ, Ellison DW, Aldape KD, Merchant TE, Bouffet E, Pfister SM, Taylor MD. “The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.” Acta Neuropathol 133(1):5-12, 2017

  7. Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyakita Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Fujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara N, Ueki K, Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, Ichimura K. “A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.” Acta Neuropathol Commun 4:79, 2016. doi: 10.1186/s40478-016-0351-2.

  8. Ichimura K, Fukushima S, Totoki Y, Matsushita Y, Otsuka A, Tomiyama A, Niwa T, Takami H, Nakamura T, Suzuki T, Fukuoka K, Yanagisawa T, Mishima K, Nakazato Y, Hosoda F, Narita Y, Shibui S, Yoshida A, Mukasa A, Saito N, Kumabe T, Kanamori M, Tominaga T, Kobayashi K, Shimizu S, Nagane M, Iuchi T, Mizoguchi M, Yoshimoto K, Tamura K, Maehara T, Sugiyama K, Nakada M, Sakai K, Kanemura Y, Nonaka M, Asai A, Yokogami K, Takeshima H, Kawahara N, Takayama T, Yao M, Kato M, Nakamura H, Hama N, Sakai R, Ushijima T, Matsutani M, Shibata T, Nishikawa R; Intracranial Germ Cell Tumor Genome Analysis Consortium. “Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy.” Acta Neuropathol 131:889-901, 2016

  9. Fukumura K, Kawazu M, Kojima S, Ueno T, Sai E, Soda M, Ueda H, Yasuda T, Yamaguchi H, Lee JH, Shishido‑Hara Y, Sasaki A, Shirahata M, Mishima K, Ichimura K, Mukasa A, Narita Y, Saito N, Aburatani H, Nishikawa R, Nagane M, Mano H. “Genomic characterization of primary central nervous system lymphoma” Acta Neuropathol 131:865-875, 2016

  10. Ohno M, Narita Y, Miyakita Y, Matsushita Y, Arita H, Yonezawa M, Yoshida A, Fukushima S, Takami H, Ichimura K, Shibui S. “Glioblastomas with IDH1/2 mutations have a short clinical history and have a favourable clinical outcome.” Jpn J Clin Oncol 46:31-39, 2016

  11. Komori K, Yanagisawa R, Miyairi Y, Sakashita K, Shiohara M, Fujihara I, Morita D, Nakamura T, Ogiso Y, Sano K, Shirahata M, Fukuoka K, Ichimura K, Shigeta H. “Temozolomide treatment for pediatric refractory anaplastic ependymoma with low MGMT protein expression.” Pediatr Blood Cancer 63:152-155, 2016

  12. Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M, Tanaka K, Fukushima S, Takami H, Arita H, Kubo A, Shuto T, Ohno M, Miyakita Y, Kocialkowski S, Sasayama T, Hashimoto N, Maehara T, Shibui S, Ushijima T, Kawahara N, Narita Y, Ichimura K. “Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.” Neuropathol Appl Neurobiol 42:279-90, 2016

  13. Ichimura K, Narita Y, Hawkins CE. “Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers.” Acta Neuropathol 129:789-808, 2015 (Review article)

  14. Takami H, Fukushima S, Fukuoka K, Suzuki T, Yanagisawa T, Matsushita Y, Nakamura T, Arita H, Mukasa A, Saito N, Kanamori M, Kumabe T, Tominaga T, Kobayashi K, Nagane M, Iuchi T, Tamura K, Maehara T, Sugiyama K, Nakada M, Kanemura Y, Nonaka M, Yokogami K, Takeshima H, Narita Y, Shibui S, Nakazato Y, Nishikawa R, Ichimura K, Matsutani M. “Human chorionic gonadotropin is expressed virtually in all intracranial germ cell tumors.” J Neurooncol 124:23-32, 2015

  15. Geisenberger C, Mock A, Warta R, Rapp C, Schwager C, Korshunov A, Nied AK, Capper D, Brors B, Jungk C, Jones D, Collins VP, Ichimura K, Bäcklund LM, Schnabel E, Mittelbron M, Lahrmann B, Zheng S, Verhaak RG, Grabe N, Pfister SM, Hartmann C, von Deimling A, Debus J, Unterberg A, Abdollahi A, Herold-Mende C. “Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain.”  Acta Neuropathol 130:419-434, 2015

  16. Takami H, Yoshida A, Fukushima S, Arita H, Matsushita Y, Nakamura T, Ohno M, Miyakita Y, Shibui S, Narita Y, Ichimura K. “Revisiting TP53 mutations and immunohistochemistry – a comparative study in 157 diffuse gliomas” Brain Pathol, 25:256-265, 2014

  17. Arita H, Narita Y, Matsushita Y, Fukushima S, Yoshida A, Takami H, Miyakita Y, Ohno M, Shibui S, Ichimura K. “Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas.” Brain Tumor Pathol 32:79-89, 2014

  18. Collins VP, Ichimura K, Di Y, Pearson D, Chan R, Thompson LC, Gabe R, Brada M, Stenning SP. “Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial.” Acta Neuropathol Commun 2:68, 2014

  19. Fukushima S, Otsuka A, Suzuki T, Yanagisawa T, Mishima K, Mukasa A, Saito N, Kumabe T, Kanamori M, Tominaga T, Narita Y, Shibui S, Kato M, Shibata T, Matsutani M, Nishikawa R, Ichimura K; On behalf of the Intracranial Germ Cell Tumor Genome Analysis Consortium (iGCT Consortium). “Mutually exclusive mutations of KIT and RAS are associated with KIT mRNA expression and chromosomal instability in primary intracranial pure germinomas.” Acta Neuropathol 127:911-925, 2014

  20. Quillien V, Lavenu A, Sanson M, Legrain M, Dubus P, Karayan-Tapon L, Mosser J, Ichimura K, Figarella-Branger D. “Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients.” J Neurooncol 116:487-496, 2014

  21. Arita H, Narita Y, Takami H, Fukushima S, Matsushita Y, Yoshida A, Miyakita Y, Ohno Y, Shibui S, Ichimura K. “TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas” Acta Neuropathol 126:939-941, 2013

  22. Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S and Ichimura K. “Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss” Acta Neuropathol 126:267-276, 2013

  23. Lambert SR, Witt H, Hovestadt V, Zucknick M, Kool M, Pearson DM, Korshunov A, Ryzhova M, Ichimura K, Jabado N, Fontebasso AM, Lichter P, Pfister SM, Collins VP, Jones DT. “Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma.” Acta Neuropathol 126:291-301, 2013

  24. Ichimura K, Nishikawa R, Matsutani M. “Molecular markers in pediatric neuro-oncology” Neuro-Oncol. 14:iv90-iv99, 2012

  25. Ichimura K.  Molecular pathogenesis of IDH mutations in gliomas. Brain Tumor Pathol 29: 131-139, 2012

  26. Okita Y, Narita Y, Miyakita Y, Ohno M, Matsushita Y, Fukushima S, Sumi M, Ichimura K, Kayama T, Shibui S. “IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy.” Int J Oncol 41:1325-36, 2012

  27. Ohno M, Narita Y, Miyakita Y, Okita Y, Matsushita Y, Yoshida A, Fukushima S, Ichimura K, Kayama T, Shibui S. “Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status” Brain Tumor Pathol 29:183-91, 2012

  28. Mulholland S, Pearson DM, Hamoudi RA, Malley DS, Smith CM, Weaver JMJ, Jones DTW, Kocialkowski S, Backlund LM, Collins VP, Ichimura K.: MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumours with IDH1 or IDH2 mutations. Int J Cancer 131:1104-1113, 2012

Publications from Refractory and Advanced Cancer Group

  1. Enari M, Matsushima-Hibiya Y, Miyazaki M, Otomo R. Studies of ATM Kinase Activity Using Engineered ATM Sensitive to ATP Analogues (ATM-AS). Methods Mol Biol. 1599:145-156, 2017
  2. Otomo R, Otsubo C, Matsushima-Hibiya Y, Miyazaki M, Tashiro F, Ichikawa H, Kohno T, Ochiya T, Yokota J, Nakagama H, Taya Y, Enari M. TSPAN12 is a critical factor for cancer-fibroblast cell contact-mediated cancer invasion. Proc Natl Acad Sci U S A. 111(52):18691-6, 2014
  3. Otsubo C, Otomo R, Miyazaki M, Matsushima-Hibiya Y, Kohno T, Iwakawa R, Takeshita F, Okayama H, Ichikawa H, Saya H, Kiyono T, Ochiya T, Tashiro F, Nakagama H, Yokota J, Enari M. TSPAN2 is involved in cell invasion and motility during lung cancer progression. Cell Rep. 24;7(2):527-38, 2014
  4. Ohata H, Miyazaki M, Otomo R, Matsushima-Hibiya Y, Otsubo C, Nagase T, Arakawa H, Yokota J, Nakagama H, Taya Y, Enari M. NuMA is required for the selective induction of p53 target genes. Mol Cell Biol. 33(12):2447-57, 2013